No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis
Open Access
- 1 October 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 13 (5) , e200185
Abstract
Background and Objectives Some patients with multiple sclerosis (MS) receiving ocrelizumab (OCR) report worsening symptoms toward the end of the 6-month infusion cycle (‘wearing off’). The objective of our study was to comprehensively assess changes in symptom burden across 2 consecutive OCR infusion cycles. Methods SYMptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS; NCT04855617) was an investigator-initiated, 2-center study of patients with MS starting or receiving OCR. Patients9 symptoms were assessed with NeuroQoL short forms, SymptoMScreen, and Work Productivity and Activity Impairment Questionnaire at the start-cycle, mid-cycle, and end-cycle time points in each of the 2 infusion cycles. Symptom scores at the 3 time points within each cycle were compared with repeated-measures ANOVA or the Friedman rank-sum test for non-normal variables. The proportions of patients with a meaningful symptomatic change from the start to the end of each infusion cycle were calculated, and patients whose symptoms improved, worsened, and stayed the same from the start to the end of the cycle were compared with respect to demographic and clinical characteristics. Results One hundred three patients with MS provided longitudinal data for analyses (mean age [SD]: 46.7 [12.2] years, 68% female, 33% non-White, disease duration: 15.5 [5] years, 41% with the Extended Disability Status Scale score >3). On a group level, NeuroQoL and SymptoMScreen scores mostly remained stable or even improved slightly toward the end of each cycle. On an individual level, symptoms remained unchanged across either cycle for most patients, and meaningful symptom worsening from the start to the end of the cycle was no more common than improvement. Meaningful change in symptoms in both cycles was very rare and generally in the direction of improvement toward the end cycle. Despite the lack of evidence for symptom worsening with a longer time from infusion, 54% of patients endorsed feeling of “wearing off” at least sometimes, most commonly as an increase in fatigue. Discussion Our prospective study failed to uncover evidence for the worsening of symptoms with a longer time from OCR infusion. These findings cast doubt on the existence of wearing off as a physiologic phenomenon in OCR-treated patients with MS. The perception of wearing off is likely the result of natural fluctuations in MS symptoms and attribution bias.Keywords
This publication has 35 references indexed in Scilit:
- SymptoMScreen: A Tool for Rapid Assessment of Symptom Severity in MS Across Multiple DomainsApplied Neuropsychology: Adult, 2016
- A population‐based study comparing multiple sclerosis clinic users and non‐users in British Columbia, CanadaEuropean Journal of Neurology, 2016
- Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary ImmunodeficiencyJournal of Clinical Immunology, 2016
- Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosisMultiple Sclerosis Journal, 2015
- Creating meaningful cut-scores for Neuro-QOL measures of fatigue, physical functioning, and sleep disturbance using standard setting with patients and providersQuality of Life Research, 2014
- Multiple Sclerosis Symptom Recrudescence at the End of the Natalizumab Dosing CycleInternational Journal of MS Care, 2014
- Neuro-QOLNeurology, 2012
- Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatientsMultiple Sclerosis Journal, 2008
- The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerationsExpert Opinion on Pharmacotherapy, 2006
- Studies of acquiescence as a factor in the true-false test.Journal of Educational Psychology, 1942